170 related articles for article (PubMed ID: 38327111)
21. Systemic therapy for the treatment of endometrial cancer.
Neri M; Peiretti M; Melis GB; Piras B; Vallerino V; Paoletti AM; Madeddu C; Scartozzi M; Mais V
Expert Opin Pharmacother; 2019 Nov; 20(16):2019-2032. PubMed ID: 31451034
[No Abstract] [Full Text] [Related]
22. Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC; Slomovitz B; Coleman RL; Pothuri B
Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
24. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
25. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract][Full Text] [Related]
26. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
27. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
[TBL] [Abstract][Full Text] [Related]
28. [Application and clinical significance of TCGA molecular classification in endometrial cancer].
Zhao LY; Dai YB; Li LW; Wang ZQ; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2021 Oct; 56(10):697-704. PubMed ID: 34823319
[No Abstract] [Full Text] [Related]
29. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.
Loukovaara M; Pasanen A; Bützow R
Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452
[TBL] [Abstract][Full Text] [Related]
30. Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors.
Wortman BG; Nout RA; Bosse T; Creutzberg CL
Curr Oncol Rep; 2019 Jul; 21(9):83. PubMed ID: 31367798
[TBL] [Abstract][Full Text] [Related]
31. An update on the current pharmacotherapy for endometrial cancer.
de Haydu C; Black JD; Schwab CL; English DP; Santin AD
Expert Opin Pharmacother; 2016; 17(4):489-99. PubMed ID: 26629895
[TBL] [Abstract][Full Text] [Related]
32. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
33. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
34. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
Perrone E; Capasso I; De Felice F; Giannarelli D; Dinoi G; Petrecca A; Palmieri L; Foresta A; Nero C; Arciuolo D; Lorusso D; Zannoni GF; Scambia G; Fanfani F
Eur J Cancer; 2023 Jun; 186():98-112. PubMed ID: 37062213
[TBL] [Abstract][Full Text] [Related]
35. Immune check-point in endometrial cancer.
De Felice F; Marchetti C; Tombolini V; Panici PB
Int J Clin Oncol; 2019 Aug; 24(8):910-916. PubMed ID: 31049759
[TBL] [Abstract][Full Text] [Related]
36. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.
Beinse G; Le Frere Belda MA; Just PA; Bekmezian N; Koual M; Garinet S; Leroy K; Letourneur F; Lusson A; Mulot C; Le Corre D; Metairie M; Delanoy N; Blons H; Gervais C; Durdux C; Chapron C; Goldwasser F; Terris B; Badoual C; Taly V; Laurent-Puig P; Borghese B; Bats AS; Alexandre J
Gynecol Oncol; 2022 Mar; 164(3):596-606. PubMed ID: 35033379
[TBL] [Abstract][Full Text] [Related]
38. [Molecular classification of endometrial carcinoma-a short summary for clinical use].
Hiller GGR; Höhn AK; Mayr D; Brambs CE; Horn LC
Pathologie (Heidelb); 2023 Nov; 44(6):392-400. PubMed ID: 37815668
[TBL] [Abstract][Full Text] [Related]
39. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods.
Bayramoglu D; Seçilmiş Kerimoğlu Ö; Bayramoğlu Z; Çintesun E; Şahin G; Karabağlı P; Çelik Ç
Ginekol Pol; 2023; 94(1):3-11. PubMed ID: 35072228
[TBL] [Abstract][Full Text] [Related]
40. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
